PULM (Pulmatrix Corp) Multiplikator forward rega marang pendapatan
The modeled P/S of Pulmatrix, Inc. (PULM) demonstrates market expectations, where the value of 46.50 reflects this status. This trend is based on the implementation of laboratory automation for molecular analysis. Prospects depend on the efficiency of lung drug delivery via iSPERSE. Growth is driven by PUR1900 trials and the search for partners for cystic fibrosis therapy, which determines the investment attractiveness of this biotech.
Rincian metrik lan analitis perusahaan Pulmatrix Corporation (PULM)
- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
- rincian valuasi buku bisnis:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Pulmatrix, Inc.|PULM - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Pulmatrix, Inc.|PULM - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Pulmatrix Corporation|PULM - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Pulmatrix|Indikator likuiditas cepet pulmatrix.com
- data bathi bisnis lan rasio investasi:
PULM - Bathi perusahaan|Bathi mangsa ngarep Pulmatrix, Inc.|PULM - Nilai perusahaan marang bathi resik|Pangali Forward P/E Pulmatrix Corp|PULM - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Pulmatrix Corporation|PULM - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Pulmatrix|PULM - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan pulmatrix.com|PULM - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Pulmatrix, Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis umum perusahaan:PULM (Pulmatrix)
The robotization of precision powder engineering at Pulmatrix, Inc. (PULM) minimizes manual labor, creating a foundation for revenue scaling. The ratio of market capitalization to projected sales allows for a valuation of this technological advantage, preventing overpayment based on unjustified optimism. By analyzing the forward P/S multiple, an investor can identify arbitrage gaps and acquire shares at a discount during maximum price drawdowns relative to expected growth.
Pesaing wigati
Rasio rega marang prakiraan pendapatan Haleon HLN|KVUE (Kenvue Inc) - Rega mangsa ngarep marang pendapatan|VRNA: Multiplikator forward rega marang pendapatan|MENS - Multiplikator Forward P/S|Ligand Pharmaceuticals (LGND) - Rasio rega marang prakiraan pendapatan|AMRX (amneal.com) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Perrigo|Multiplikator forward rega marang pendapatan Alvotech S.A. (ALVO)|Multiplikator Forward P/S LQDA|Multiplikator Forward P/S Galapagos Corp (GLPG)|ANI Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake MNKD (mannkindcorp.com)|AMPH - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan PCRX (Pacira Pharmaceuticals)|SPRY: Multiplikator Forward P/S|TBPH - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan AQST|Kapitalisasi marang prakiraan pendapatan SCPH (scPharma)|Multiplikator forward rega marang pendapatan TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharma) - Rega forward marang dodolan|Multiplikator Forward P/S SXTC (China SXT Pharmaceuticals, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Eupraxia Pharmaceuticals, Inc. (EPRX)|BHST - Rasio rega marang prakiraan pendapatan|EXOZ (invizyne.com) - Kapitalisasi marang prakiraan pendapatan|ORMP: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Entera Bio|Multiplikator forward rega marang pendapatan HYFT|ABVC BioPharma, Inc (ABVC) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Cumberland Pharmaceuticals (CPIX)|QNTM: Rega mangsa ngarep marang pendapatan|FibroGen - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Telomir Pharmaceuticals Inc TELO|RANI - Rasio rega marang prakiraan pendapatan|SNYR: Rasio rega marang prakiraan pendapatan|rallybio.com (RLYB) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Lexaria Bioscience Corp.|Rasio rega marang prakiraan pendapatan Pheton Holdings Limited|Aptorum - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S LYRA|IBO (Impact BioMedical, Inc.) - Rega forward marang dodolan|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|Multiplikator Forward P/S cbdMD Inc. YCBD|PRFX - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CYTO (Altamira Therapeutics)|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan OptiNose Corp|PIRS (Pieris Pharmaceuticals) - Multiplikator Forward P/S|Multiplikator Forward P/S procapsgroup.com|Multiplikator forward rega marang pendapatan PTPI (Petros Pharmaceuticals, Inc.)|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|TFF Pharmaceuticals, Inc (TFFP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep
